Overview

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

Phase:

Phase 3

Details

Lead Sponsor:

Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited